When a drug developer trades below the cash on its balance sheet, the market is saying it expects much of that cash to be spent without a return. Sometimes that view is right. The Desk screened liquid US listed healthcare names between $50 million and $500 million for net cash above market value, then read each company's latest filings for cash, liabilities and how fast the money is going out.
The four below are ranked by cash as a multiple of market value. Cash is a starting point, not a floor: none of these companies is planning to return it to shareholders.
Screen: stockanalysis.com market data, pulled October 20, 2026. Balance sheets: each company's Form 10-Q for the quarter ended June 30, 2026, plus later 8-K filings named below.
1. LENZ Therapeutics (Nasdaq: LENZ)
Cash and securities: 2.1 times market value · NEUTRAL
LENZ sells VIZZ, an aceclidine eye drop for presbyopia, the age related loss of near vision. It held $220.0 million in cash, cash equivalents and marketable securities at June 30, 2026, against total liabilities of $17.3 million.
The launch is early. Product sales were $1.7 million in the June quarter on about 27,000 packs, 9% more packs than in the March quarter, and the company counted more than 13,000 prescribers since launch. License revenue added $3.8 million. Operating cash outflow was $72.3 million in the first half, and the June quarter net loss was $31.9 million. LENZ added a telehealth prescribing channel in July 2026.
Valuation at Publication: LENZ
Price data as of: October 19, 2026 close. Balance sheet data as of: June 30, 2026.
Source: LENZ Therapeutics Form 10-Q for the quarter ended June 30, 2026, filed August 11, 2026; Form 8-K filed August 11, 2026 (Exhibit 99.1). Price: stockanalysis.com. Market cap uses 31,420,343 shares from the 10-Q cover and is Desk arithmetic.
2. Upstream Bio (Nasdaq: UPB)
Cash and investments: 1.7 times market value · NEUTRAL
Upstream Bio is developing verekitug for severe asthma and chronic rhinosinusitis with nasal polyps. It held $79.4 million in cash and $181.9 million in short term investments at June 30, 2026, $261.3 million in total, against liabilities of $10.2 million.
The cash has a long road to cover. On September 1 the company set out Phase 3 plans: one placebo controlled study in each indication, about 1,500 patients across both, starting in the first quarter of 2027, with a potential launch as early as 2030 if results support a filing. First half operating cash outflow was $83.5 million. The shares traded between $2.74 and $33.68 over the past 52 weeks.
Valuation at Publication: UPB
Price data as of: October 19, 2026 close. Balance sheet data as of: June 30, 2026.
Source: Upstream Bio Form 10-Q for the quarter ended June 30, 2026, filed August 11, 2026; Form 8-K filed September 1, 2026 (Item 8.01). Price: stockanalysis.com. Market cap uses 54,771,041 shares from the 10-Q cover and is Desk arithmetic.
3. Tonix Pharmaceuticals (Nasdaq: TNXP)
Cash: 1.7 times market value · NEUTRAL
Tonix markets TONMYA, a sublingual cyclobenzaprine tablet for fibromyalgia in adults. On October 15 it gave preliminary, unaudited third quarter figures: TONMYA net revenue of $14.0 million to $15.0 million, and cash and equivalents of about $162.8 million at September 30, 2026. June quarter revenue was $13.5 million.
Tonix had total liabilities of $31.8 million at June 30. It used $84.6 million in operating cash in the first half, and its June quarter net loss was $40.6 million. Revenue is growing from a low base, but the business is still spending several times what it brings in.
Valuation at Publication: TNXP
Price data as of: October 19, 2026 close. Balance sheet data as of: September 30, 2026 for cash (preliminary, Form 8-K); June 30, 2026 for liabilities.
Source: Tonix Pharmaceuticals Form 8-K filed October 15, 2026 (Item 2.02); Form 10-Q for the quarter ended June 30, 2026, filed August 10, 2026. Price: stockanalysis.com. Market cap uses 17,151,024 shares from the 10-Q cover and is Desk arithmetic.
4. Atrium Therapeutics (Nasdaq: RNA)
Cash and investments: 1.6 times market value · NEUTRAL
Atrium was separated from Avidity Biosciences in connection with Avidity's merger agreement with Novartis. Its lead candidate, ATR 1072, is an siRNA therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome. At June 30, 2026 it held $72.3 million in cash and $191.6 million in short term investments, $263.9 million in total, against liabilities of $65.9 million.
It is also the one name here adding cash. On October 8 Atrium agreed a private placement of shares, pre funded warrants and warrants for about $50 million in gross proceeds, and said the money, with existing cash, should fund operations through 2028. After the offering it expects 22,276,027 shares outstanding. First half operating cash outflow was $35.1 million.
Valuation at Publication: RNA
Price data as of: October 19, 2026 close. Balance sheet data as of: June 30, 2026.
Source: Atrium Therapeutics Form 10-Q for the quarter ended June 30, 2026, filed August 13, 2026; Form 8-K filed October 8, 2026 (Items 1.01, 3.02, 8.01). Price: stockanalysis.com. Market cap uses the 22,276,027 post offering shares and is Desk arithmetic.
Risks
- Burn rate. LENZ, Upstream and Tonix each used more than $70 million of operating cash in the first half of 2026. At that pace, a cash cushion above market value shrinks within a few quarters.
- Launch economics. LENZ and Tonix are selling approved products, but revenue in both cases is small next to spending.
- Long timelines. Upstream does not plan to start Phase 3 until 2027 and points to 2030 as the earliest launch.
- Dilution. Atrium's October placement adds shares and warrants, and each of the other three is spending faster than it earns.
- Against the neutral read. All four have cash well above total liabilities, and two already sell an approved product, which is more than many microcap biotechs can say.
Source: the filings named above. Multiples of market value are Desk arithmetic.
The Desk's Read: Neutral
Trading below cash is a measure of doubt, not a margin of safety. For each name the useful question is how many quarters of spending the cash buys and what has to happen before it runs out: pack growth at LENZ, TONMYA revenue at Tonix, a Phase 3 start at Upstream, and progress on ATR 1072 at Atrium.
Sources
- LENZ Therapeutics, Form 10-Q for the quarter ended June 30, 2026, and Form 8-K filed August 11, 2026
- Upstream Bio, Form 10-Q for the quarter ended June 30, 2026, and Form 8-K filed September 1, 2026
- Tonix Pharmaceuticals, Form 10-Q for the quarter ended June 30, 2026, and Form 8-K filed October 15, 2026
- Atrium Therapeutics, Form 10-Q for the quarter ended June 30, 2026, and Form 8-K filed October 8, 2026
- stockanalysis.com, LENZ, UPB, TNXP and RNA overview pages, close of October 19, 2026
Disclosure
This article is independent editorial content and reflects the author's opinion and analysis as of the date of publication. It is not investment advice and should not be relied on as the basis for any investment decision. MicroCap Desk and its contributors received no compensation of any kind — cash, securities, or otherwise — from any company mentioned, or from any third party, in connection with this article. The author holds no position in any security mentioned. Information is drawn from sources believed reliable but is not guaranteed accurate or complete. Microcap securities carry a high risk of loss. Do your own research. See our full Disclosure.
